Status:
COMPLETED
Effect of Aspirin on Abacavir-induced Platelet Reactivity in HIV-infected Patients
Lead Sponsor:
Azienda Ospedaliera di Perugia
Conditions:
HIV-infected Patients
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The specific research questions addressed in the present study are: * to investigate the impact of treatment with low-dose aspirin in HIV-1-infected patients treated with ABC and test it would result...
Detailed Description
Highly active antiretroviral therapy (HAART) may reduce the deleterious effects of HIV on the cardiovascular system by decreasing viral load and chronic inflammation; however some antiretrovirals enha...
Eligibility Criteria
Inclusion
- a viral load \<50 copies per millilitre
- ABC treatment for at least 6 months
Exclusion
- age younger than 18
- nonsteroidal anti-inflammatory drug use in the past week (including aspirin), renal failure (creatinine clearance \<30 mL/min), platelet count \<100,000/microL, history of gastrointestinal bleeding within the last 6 months, presence of coexisting inflammatory disease, cancer, active bacterial or fungal infection, bleeding history, oral anticoagulant therapy and allergy to aspirin
Key Trial Info
Start Date :
January 2 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 12 2017
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT03316534
Start Date
January 2 2017
End Date
October 12 2017
Last Update
October 20 2017
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.